![](/img/cover-not-exists.png)
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort
d’Arminio Monforte, Antonella, Lorenzini, Patrizia, Cozzi-Lepri, Alessandro, Mussini, Cristina, Castagna, Antonella, Baldelli, Franco, Puoti, Massimo, Vichi, Francesca, Maddaloni, Adelaide, Lo Caputo,Language:
english
Journal:
HIV Clinical Trials
DOI:
10.1080/15284336.2018.1440691
Date:
March, 2018
File:
PDF, 723 KB
english, 2018